Skip to content
OpenCapital
Get started

Outlook Therapeutics, Inc. OTLK Q2 2025 earnings

Reported August 14, 2025 · Before market open

Revenue$1.5MMiss by $4.3MDiluted EPS-$0.44Miss by $0.02
Revenue estimate$5.8M
EPS estimate-$0.42

Next report

Aug 13, 2026 (In 3 weeks)
Revenue estimate$4.8M
EPS estimate-$0.09

Versus estimates

Revenue

Q1 2026$128.0KMiss by $4.3MQ4 2025-$1.2MMiss by $4.4MQ3 2025-$91.8KMiss by $5.9M
Q2 2025$1.5MMiss by $4.3M

Diluted EPS

Q1 2026-$0.16Miss by $0.04Q4 2025-$0.22Miss by $0.05Q3 2025-$0.22Beat by $0.04
Q2 2025-$0.44Miss by $0.02
Q1 2025-$0.40Beat by $0.15Q4 2024-$0.89Miss by $0.04

Ask the moment Outlook Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Outlook Therapeutics, Inc. report Q2 2025 earnings?
Outlook Therapeutics, Inc. (OTLK) reported Q2 2025 earnings on August 14, 2025 before market open.
What were Outlook Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Outlook Therapeutics, Inc. reported revenue of $1.5M and diluted EPS of $-0.44 for Q2 2025.
Did Outlook Therapeutics, Inc. beat estimates in Q2 2025?
Revenue missed the consensus estimate of $5.8M by $4.3M. EPS missed the consensus estimate of $-0.42 by $0.02.
How did Outlook Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 47.0% from $-0.83.
Where can I find Outlook Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001558370-25-011588) directly on SEC EDGAR. The filing index links above go to sec.gov.